Xenon Pharmaceuticals (XENE) Amortizatization of Intangibles (2018 - 2026)
Xenon Pharmaceuticals (XENE) reported Amortizatization of Intangibles of $338000.0 for Q1 2026, up 4.97% year-over-year from $322000.0 in Q1 2025, and up 1.2% quarter-over-quarter from $334000.0 in Q4 2025.
Xenon Pharmaceuticals (XENE) Amortizatization of Intangibles (2018 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has 7 years of Amortizatization of Intangibles data on file, last reported at $338000.0 in Q1 2026.
- Amortizatization of Intangibles for Q1 2026 came in at $338000.0, up 4.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 million (up 4.89% YoY), and the FY2025 annual result was $1.3 million, up 4.7% from the prior year.
- Amortizatization of Intangibles improved to $338000.0 in Q1 2026 per XENE's latest filing, from $334000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $338000.0 in Q1 2026 and troughed at -$4.6 million in Q4 2023.
- A 4-year average of -$173100.0 and a median of $320500.0 in 2024 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2024 and 2025: Amortizatization of Intangibles jumped 106.88% in 2024, then increased 4.21% in 2025.
- A 4-year view of Amortizatization of Intangibles shows it stood at -$4.6 million in 2023, then jumped by 106.88% to $319000.0 in 2024, then grew by 4.7% to $334000.0 in 2025, then grew by 1.2% to $338000.0 in 2026.
- Business Quant data shows XENE's Amortizatization of Intangibles at $338000.0 in Q1 2026, $334000.0 in Q4 2025, and $330000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Xenon Pharmaceuticals | 4.61 Bn | 4.61 Bn | - | 338,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 338,000.00 |
| Mar 31, 2026 | 338,000.00 |
| Dec 31, 2025 | 334,000.00 |
| Dec 31, 2025 | 334,000.00 |
| Sep 30, 2025 | 330,000.00 |
| Sep 30, 2025 | 330,000.00 |
| Jun 30, 2025 | 327,000.00 |
| Jun 30, 2025 | 327,000.00 |
| Mar 31, 2025 | 322,000.00 |
| Mar 31, 2025 | 322,000.00 |
| Dec 31, 2024 | 319,000.00 |
| Dec 31, 2024 | 319,000.00 |
| Sep 30, 2024 | 315,000.00 |
| Sep 30, 2024 | 315,000.00 |
| Jun 30, 2024 | 311,000.00 |
| Jun 30, 2024 | 311,000.00 |
| Mar 31, 2024 | 309,000.00 |
| Mar 31, 2024 | 309,000.00 |
| Dec 31, 2023 | -4.64 Mn |
| Dec 31, 2023 | -4.64 Mn |